/

Empresas

Ka

No verificado

Kaerus Bioscience

Sobre qué escribimos

BiologíaBiotecnologíaFarmacéuticaMedicina Salud BienestarSanidad

2 Comunicados de prensa

Ver todos los comunicados de prensa

14/05/2025

Farmacéutica

Sanidad

Biología

Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS)

Fuente

Kaerus Bioscience

Editor

1.00

0

25/07/2024

Biotecnología

Medicina Salud Bienestar

Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Fuente

Kaerus Bioscience

Editor

1.00

0

Seguidores

0

Compatibilidad

0